Precigen PGEN Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

BridgeBio PharmaBBIO

——

AmgenAMGN

——

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Market cap$1.93B+213%

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Precigen's debt instrument, unamortized discount (premium) and debt issuance costs, net?: Precigen (PGEN) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $6.48M in Q1 2026.